SUPRIYA

Supriya Lifescience Share Price

₹644.40 +35.5 (5.83%)

17 Nov, 2024 17:53

SIP TrendupStart SIP in SUPRIYA

Start SIP

Performance

  • Low
  • ₹605
  • High
  • ₹649
  • 52 Week Low
  • ₹240
  • 52 Week High
  • ₹690
  • Open Price₹609
  • Previous Close₹609
  • Volume392,479

Investment Returns

  • Over 1 Month + 12.54%
  • Over 3 Month + 26.38%
  • Over 6 Month + 70.63%
  • Over 1 Year + 162.27%
SIP Lightning

Smart Investing Starts Here Start SIP with Supriya Lifescience for Steady Growth!

Invest Now

Supriya Lifescience Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 32.9
  • PEG Ratio
  • 0.6
  • Market Cap Cr
  • 5,186
  • P/B Ratio
  • 6.4
  • Average True Range
  • 31.62
  • EPS
  • 19.57
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 17.76
  • RSI
  • 58.69
  • MFI
  • 85.09

Supriya Lifescience Financials

Supriya Lifescience Technicals

EMA & SMA

Current Price
₹644.40
+ 35.5 (5.83%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹616.12
  • 50 Day
  • ₹584.28
  • 100 Day
  • ₹535.31
  • 200 Day
  • ₹466.35

Resistance and Support

632.75 Pivot Speed
  • R3 703.90
  • R2 676.30
  • R1 660.35
  • S1 616.80
  • S2 589.20
  • S3 573.25

What's your outlook on Supriya Lifescience?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Supriya Lifescience is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) with over 38 APIs across various therapeutic segments. It exports to 86 countries, supplying high-quality APIs for pharmaceuticals, nutraceuticals, and personal care industries.

Supriya Lifescience has an operating revenue of Rs. 624.98 Cr. on a trailing 12-month basis. An annual revenue growth of 24% is outstanding, Pre-tax margin of 29% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 45% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -4% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 85 which is a GOOD score indicating consistency in earnings, a RS Rating of 89 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 55 indicates it belongs to a fair industry group of Medical-Supplies and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Supriya Lifescience Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-28 Quarterly Results
2024-08-10 Quarterly Results
2024-05-28 Audited Results & Final Dividend
2024-02-07 Quarterly Results
2023-11-07 Quarterly Results

Supriya Lifescience F&O

Supriya Lifescience Shareholding Pattern

68.3%
0.62%
3.23%
6.03%
0%
21.82%

About Supriya Lifescience

  • NSE Symbol
  • SUPRIYA
  • BSE Symbol
  • 543434
  • ISIN
  • INE07RO01027

Similar Stocks to Supriya Lifescience

Supriya Lifescience FAQs

Supriya Lifescience share price is ₹644 As on 17 November, 2024 | 17:39

The Market Cap of Supriya Lifescience is ₹5186.3 Cr As on 17 November, 2024 | 17:39

The P/E ratio of Supriya Lifescience is 32.9 As on 17 November, 2024 | 17:39

The PB ratio of Supriya Lifescience is 6.4 As on 17 November, 2024 | 17:39

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23